Titan Medical Inc

Titan Medical, Inc. engages in the research and development of a computer-assisted robotic surgical technology for application in minimally invasive surgery (MIS). Its portfolio, the Enos™ system, is a robotic single access surgery with dual 3D and 2D definition vision systems, multi-articulating instruments, and a surgeon workstation. The company was founded on July 28, 2008 and is headquartered in Toronto, Canada.

Quantum International Corp. operates as an emerging robotics innovation company. It identifies and develops innovative products in the robotics, consumer electronics and lifestyle enhancement products. The company was founded on September 25, 2001 and is headquartered in Centennial, CO.

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of an innovative single access robotic-assisted surgery system, today received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the company's common shares listed on Nasdaq was below

Titan Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Titan Medical is developing single-access robotic assisted surgical technologies to be incorporated in its flagship Enos minimally invasive surgery system. Enos system is a mobile MIS cart integrated with a surgeon workstation. The Company intends to initially pursue gynecologic surgical indications.

Titan Medical: Developing Single-Access Robotic Assisted Surgical Technologies

TORONTO--(BUSINESS WIRE)--Titan Medical Announces CEO Transition

Titan Medical Announces CEO Transition

Titan Medical Inc.'s (TMDI) CEO David McNally on Q3 2021 Results - Earnings Call Transcript

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of its innovative surgical technologies for robotic-assisted surgery that requires a single patient access point, today announced financial results for the three and nine months ended September 30, 2021. During the third quarter of 2021 and in recent weeks, Titan made significant advancements including commencing the transfer of the design document

Titan Medical Reports Third Quarter 2021 Financial Results

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of its innovative surgical technologies for robotic single access surgery, today announced changes to its Surgeon Advisory Board (SAB) comprised of industry leaders in single access and robotic-assisted surgery. The SAB will work cohesively with management to advance the company's Enos™ robotic single access surgical system through clinical studies to

Titan Medical Announces Expansion of Surgeon Advisory Board

TORONTO--(BUSINESS WIRE)--Titan Medical to Report Third Quarter 2021 Financial Results on November 11, 2021

Titan Medical to Report Third Quarter 2021 Financial Results on November 11, 2021

Dover, Delaware--(Newsfile Corp. - October 28, 2021) - Encode Ideas, L.P. Initiates Research on Titan Medical, Inc. (NASDAQ: TMDI) (TSX: TMD). The full research publication is available here and available on our website at www.encodelp.com. A summary follows:Encode Ideas, L.P. is initiating coverage on Titan Medical, Inc. as a High Conviction Investment Idea. Titan is a medical device company headquartered in Toronto, Ontario with R&D facilities in Chapel Hill, North Carolina, and is focused...

Encode Ideas, L.P. Announces the Initiation of Research Coverage on Titan Medical, Inc.

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has completed its scheduled pre-clinical studies with its Enos™ robotic single access surgical system, performed in accordance with FDA's good laboratory practice (GLP) regulations. GLP is a set of principles intended to assure the quality and integrity of non-clinical laboratory

Titan Medical Announces Completion of Pre-Clinical GLP Studies

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of its innovative surgical technologies for robotic single access surgery, today announced that David McNally, President and CEO of Titan Medical, will present an overview of the company and its Enos™ robotic single access surgical system and participate in one-on-one investor meetings at two upcoming investor conferences: The Oppenheimer Virtual Fall

Titan Medical to Participate in Upcoming Investor Conferences in September

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of its innovative surgical technologies for robotic single access surgery, today announced that David McNally, President and CEO of Titan Medical, will present an overview of the company and its Enos™ robotic single access surgical system at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021. The presentation wil

Titan Medical to Participate in H.C. Wainwright Investor Conference

Titan Medical's (TMDI) CEO David McNally on Q2 2021 Results - Earnings Call Transcript

TORONTO--(BUSINESS WIRE)--Titan Medical Announces Second Quarter 2021 Financial Results

Titan Medical Reports Second Quarter 2021 Financial Results

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that the company plans to issue its second quarter 2021 financial results prior to market opening on Wednesday, August 11, 2021. In addition, management will host an investor audio webcast at 8:30 a.m. ET to discuss financial results and business highlights. Speakers will include David Mc

Titan Medical to Report Second Quarter 2021 Financial Results on August 11, 2021

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the appointment of Tammy Carrea as Vice President of Quality and Regulatory Affairs. “We are delighted that Tammy has joined Titan Medical's leadership team as we advance our Enos™ robotic single access surgery system toward human clinical studies,” said David McNally, President and Chief

Titan Medical Announces Appointment of Tammy Carrea as Vice President of Quality and Regulatory Affairs

TORONTO--(BUSINESS WIRE)--Titan Medical to Participate in AGP Investor Conference

Titan Medical to Participate in Alliance Global Partners Virtual MedTech Summer Investor Conference

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq:TMDI; TSX:TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the appointment of Stephen Lemieux as the Chief Financial Officer of the Company. Mr. Lemieux has more than 18 years of experience working in Nasdaq and TSX listed companies primarily focused in the health care industry. Mr. Lemieux has been involved with or led numerous debt and equity fin

Titan Medical Announces Appointment of New Chief Financial Officer

Robotic-assisted single access surgery might sound like a future pipe dream for the medical community, but the technology exists today, and Titan Medical Inc. (NASDAQ: TMDI; TSX: TMD) is paving the way to bringing its exciting technology to surgeons. Titan has one goal in mind: Develop leading-edge robotic tools and accessories that access the body through a single access point to help surgeons in the operating room and patients in recovery.

Titan Medical: Innovation Leader in Robotic-assisted, Single Access Surgery Technology

Medtronic

Titan Medical Inc (NASDAQ: TMDI) has received $10 million under the second technical milestone under the development and license agreement with Medtronic plc (NYSE: MDT). The development and license agreement provides for developing robotic-assisted surgical technologies for Titan and Medtronic in their respective businesses.

Titan Medical Stock Jumps After Medtronic's $10M Second Milestone Payment

The stock price of Titan Medical Inc. (NASDAQ: TMDI) increased by over 9% pre-market. This is why it happened.

TMDI Stock Price: Over 9% Increase Pre-Market Explanation

Completion of Second Technical Milestone Marks Third Achievement Under Development and License Agreement Completion of Second Technical Milestone Marks Third Achievement Under Development and License Agreement

Titan Medical Receives License Fee of $10 Million Upon Achievement of Milestone Under Medtronic Development Agreement

TORONTO, May 24, 2021 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the addition of Deepak Basra as Vice President, Strategy and Business Development to the leadership team. In this newly created role, Mr. Basra will oversee Titan's corporate development and strategic planning.

Titan Medical Announces Addition of Deepak Basra as Vice President, Strategy and Business Development

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that David McNally, President and CEO of Titan Medical, will present an overview of the company and its Enos™ robotic single access surgical system at the Oppenheimer MedTech Summit Investor Conference on Wednesday, May 26, 2021 available at 8:00 a.m. ET. A link to the presentation will b

Titan Medical to Present at Oppenheimer MedTech Summit Investor Conference

Titan Medical's (TMDI) CEO David McNally on Q1 2021 Results - Earnings Call Transcript

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces financial results for the three months ended March 31, 2021. During the first quarter of 2021 the company raised proceeds of $34.5 million from two equity financings and $10 million from the exercise of warrants issued to investors in previous offerings. Titan also announces changes to its boar

News for Titan Medical Inc Stock (TMDI)